AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03775291 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Simultaneous assessment of sleep apnea by polysomnogram and wearable device
Description: Characterization of sleep apnea by lab-based polysomnogram
Study NCT03092271 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stepped Care for Suicide Prevention
Description: ZSQI plus Stepped Care for Suicide Prevention
Study NCT03092271 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Zero Suicide Quality Improvement
Description: ZSQI
Study NCT03092271 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Zero Suicide Quality Improvement
Description: ZSQI
Study NCT02305888 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEO 43204
Description: Treatment of actinic keratosis
Study NCT01546727 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Motivational Interviewing
Description: Motivational interviewing will be delivered at the same frequency at the behavioral intervention with 4 in-person visits spaced at the first visit, month 3 and month 5. Phone calls will be conducted weekly during the first 3 months and every other week during months 4 through 6.
Study NCT04194008 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nerivio
Description: A remote electrical neuromodulation (REN) device for the acute treatment of migraines.The device delivers transcutaneous electrical stimulation to the upper arm to induce conditioned pain modulation (CPM) that activates a descending endogenous analgesic mechanism. The treatment is self-administered and controlled by a smartphone application.
Study NCT03234608 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: AASPIRE Healthcare Toolkit
Description: The AASPIRE Healthcare Toolkit includes a variety of resources (information, worksheets, checklists, links) for patients and providers. The centerpiece of the toolkit is the Autism Healthcare Accommodations Tool, which allows a patient or their supporter to create a personalized accommodations report for the patient's provider. Intervention patients will use the toolkit and create an AHAT report. Intervention clinics will receive a copy of each patient's AHAT report, place it in the medical record, and share it with the patient's PCP and other staff.
Study NCT01819064 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atropine
Description: intravenous atropine affect on heart rate
Study NCT00976170 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GC33(RO5137382)
Description: IV administration at 6 escalating dose levels.
Study NCT00976170 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Oral administration at 400mg twice daily or 400mg once daily
Study NCT03862716 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IDegLira
Description: Dose is titrated to achieve fasting normoglycemia
Study NCT03862716 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec
Description: In those who need additional insulin or who cannot tolerate IDegLira, insulin degludec will be used. Dose is titrated to achieve fasting normoglycemia.
Study NCT03862716 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Dose is titrated to 2000 mg per day or maximal tolerated dose
Study NCT03862716 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle Therapy
Description: Lifestyle intervention includes individualized dietary and exercise advice targeting at least 5% weight loss with frequent visits and coaching for goal reinforcement, behavior modification and problem-solving
Study NCT00335556 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan Hydrochloride
Description: Given IV
Study NCT00335556 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional Surgery
Description: Patients undergo resection
Study NCT03048461 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Platelet Rich Plasma Prep System
Description: intradermal injections of platelet rich plasma to an area of alopecia
Study NCT03048461 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Platelet Rich Plasma Prep System
Description: intradermal injections of platelet rich plasma to an area of alopecia
Study NCT03048461 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: intradermal injections to an area of alopecia
Study NCT02966873 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-Acetylcysteine (NAC) Treatment
Description: Participant will receive 12 weeks of Active Treatment NAC (2400 mg) daily. The study medication will be provided in blister packs in the form of 600 mg tablets. Each participant will be asked to take two (2) 600 mg tablets in the morning and two (2) 600 mg tablets in the evening.
Study NCT02966873 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Description: Participant will receive 12 weeks of weekly cognitive-behavioral therapy, medication management, and AE monitoring.
Study NCT02966873 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Cognitive Behavioral Therapy (CBT)
Description: Participant will receive 12 weeks of weekly cognitive-behavioral therapy, medication management, and AE monitoring.
Study NCT02966873 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Inactive Placebo Oral Capsule
Description: Participant will receive 12 weeks of inactive placebo. The study medication will be provided in blister packs in the form of 600 mg tablets. Each participant will be asked to take two (2) 600 mg tablets in the morning and two (2) 600 mg tablets in the evening.
Study NCT02966873 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Functional magnetic resonance imaging (fMRI)
Description: Participants will be given the option to complete Functional magnetic resonance imaging (fMRI) at two timepoints (pre-treatment and end of treatment).
Study NCT02966873 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Functional magnetic resonance imaging (fMRI)
Description: Participants will be given the option to complete Functional magnetic resonance imaging (fMRI) at two timepoints (pre-treatment and end of treatment).
Study NCT02966873 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Proton magnetic resonance spectroscopy (MRS) Imaging
Description: Participants will be given the option to complete magnetic resonance spectroscopy (MRS) at two timepoints (pre-treatment and end of treatment).
Study NCT02966873 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Proton magnetic resonance spectroscopy (MRS) Imaging
Description: Participants will be given the option to complete magnetic resonance spectroscopy (MRS) at two timepoints (pre-treatment and end of treatment).
Study NCT01462227 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone High Dose
Description: Naltrexone 100mg for two administrations.
Study NCT01462227 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone Low Dose
Description: Naltrexone 50mg for two administrations.
Study NCT05143619 — intervention group
Intervention type: OTHER
Intervention: Survey Administration
Description: Complete surveys
Study NCT00942773 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Voriconazole
Study NCT06710041 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Kinesiotape
Description: Kinesiotape, when applied with a specific method and tension, significantly reduces the pressure on the median nerve by extending the transverse carpal ligament. It regulates edema under the skin and improves lymphatic and blood circulation. It reduces muscle spasms, eases the movement of tendons and fascia, and reduces pain through neurological suppression
Study NCT06710041 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Tendon and nerve gliding exercise
Study NCT06710041 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Exercise
Description: Tendon and nerve gliding exercise
Study NCT06710041 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Exercise
Description: Tendon and nerve gliding exercise
Study NCT06710041 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham taping
Description: In the sham taping group, kinesiotape was applied with two I bands without stretching and without having the proper position. This group was considered as the placebo group.
Study NCT00335556 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV
Study NCT03119038 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivicaine + epinephrine
Description: Intraoperative periarticular injection of 30 mL of a 0.25% solution bupivacaine with epinephrine
Study NCT03119038 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: Intraoperative periarticular injection of 30 mL of a 0.25% solution bupivacaine without epinephrine
Study NCT03119038 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: Intraoperative periarticular injection of 300 mg of 0.5% ropivacaine
Study NCT03119038 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketorolac
Description: Intraoperative periarticular injection of 30 mg
Study NCT03119038 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clonidine Injection
Description: Intraoperative periarticular injection of 100 mcg clonidine in a 100 mL 0.9% saline solution
Study NCT02951988 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rapastinel
Description: Rapastinel pre-filled syringes for IV injections.
Study NCT02951988 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo-matching Rapastinel
Description: Placebo-matching rapastinel pre-filled syringes for weekly IV injections.
Study NCT01883128 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Whole Body MRI
Description: Full parametric MRI using T1W, T2W, Diffusion-weighted and dynamic-contrast-enhanced images at 3Tesla
Study NCT01883128 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Focal Salvage Therapy
Description: Cryotherapy and HIFU will be used to targeted the areas of tumor only with a margin of normal tissue.
Study NCT00335556 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV
Study NCT01830387 — intervention group
Intervention type: DEVICE
Intervention: Polymetric clips
Description: The study team will prospectively enroll subjects with a diagnosis of appendicitis who are scheduled for laparoscopic appendectomy to have Hem-o-Lok® clips used for closure of the appendiceal stump.
Study NCT01830387 — intervention group
Intervention type: OTHER
Intervention: Endoscopic Staplers
Description: The study team will retrospectively identify patients who have undergone laparoscopic appendectomy by performing a database search. The operative notes will be reviewed for these patients to select patients who underwent ligation of the appendix with an endoscopic stapler.
Study NCT00335556 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV
Study NCT00335556 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dactinomycin
Description: Given IV
Study NCT00335556 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate
Description: Given IV
Study NCT00511199 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NOMAC-E2
Description: Nomegestrol Acetate and Estradiol Tablets, 2.5 mg~NOMAC and 1.5 mg E2 taken once daily from Day 1 of menstrual period up to and including Day 28 for 13 consecutive 28-day menstrual cycles (1 year).
Study NCT00511199 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DRSP-EE
Description: Drospirenone and Ethinyl Estradiol Tablets, 3 mg DRSP and 30 mcg EE taken once daily from Day 1 of menstrual period up to and including Day 28 for 13 consecutive 28-day menstrual cycles (1 year).
Study NCT00335556 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo radiotherapy
Study NCT00335556 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT00797225 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Leuprorelin Acetate Depot
Description: Leuprorelin acetate depot injection 3.75 mg administered as an intramuscular injection
Study NCT00797225 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elagolix
Description: Elagolix tablets administered orally
Study NCT00797225 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Placebo to Elagolix
Description: Placebo tablet administered orally
Study NCT00797225 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to Elagolix
Description: Placebo tablet administered orally
Study NCT00797225 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to Leuprorelin Acetate
Description: Saline solution administered as an intramuscular injection
Study NCT00797225 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to Leuprorelin Acetate
Description: Saline solution administered as an intramuscular injection
Study NCT03383211 — intervention group
Intervention type: OTHER
Intervention: RNAseq
Description: Transcriptome profiling of peripheral blood using RNA sequencing technology
Study NCT04315922 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Microbiome and Plasma Characterisation
Description: Flow Cytometry, Mass-Spectometry, Shotgun-Sequencing
Study NCT02609503 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab, 200 mg IV during cycle visits every 3-weeks for up to 6 cycles, or until toxicities are no longer tolerable
Study NCT03730012 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gilteritinib
Description: Oral tablet
Study NCT03730012 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atezolizumab
Description: Intravenous infusion
Study NCT03969511 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: direct angio-suite admission
Description: Upon arrival in angio-suite and after neurological examination with scoring NIHSS and mRS, and performing the blood sample, patient undergoes rotational CBCT in order to confirm ischemic stroke. Mechanical thrombectomy is the performed as well as intravenous thrombolysis when contraindications are excluded.
Study NCT03969511 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: standard management
Description: Arrival is in the MRI/CT-scan room or in the emergency department. Directly after neurological examination and blood sample, patient undergoes imaging and then bridging therapy when indicated.
Study NCT01843595 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: REFIT Intervention
Description: The intervention will include 2 face-to-face group meetings, weekly check-in sessions, weekly tailored feedback, and weekly lessons focused on specific weight loss behaviors. All participants will be encouraged increase their physical activity to approximately 250 minutes of moderate to vigorous physical activity per week.
Study NCT00460369 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sulfadoxine-pyrimethamine
Description: tablets 1,25/25 mg~1 tablet per 20 kg of body weight Single drug intake
Study NCT00460369 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: artemether-lumefantrine
Description: tablets 20/120 mg~* 1 tablet twice daily for 3 days below 15 kg of bodyweight~* 2 tablets twice daily for 3 days below 24 kg of bodyweight~* 3 tablets twice daily for 3 days below 35 kg of bodyweight
Study NCT00460369 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: amodiaquine-artesunate coformulation
Description: one 25mg/67,5mg tablet, once daily for 3 days below 9 kg~one 50/135mg tablet, once daily for 3 days below 18 kg
Study NCT01394718 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous Acetaminophen
Description: Scheduled doses of 15 mg/kg of IV acetaminophen will be administered to the treatment arm of the study for a total of 8 doses over a 48 hour period post-operatively.
Study NCT01394718 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline placebo will be given at the time of skin closure intra-operatively and will continue to receive IV saline for 44 hours post-operatively. Doses will be administered every 6 hours (total of 8 doses).
Study NCT04072575 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PP6M injection Dose 1
Description: Participants will receive Dose 1 PP6M intramuscular (IM) injection at Visit 1 (Day) then once every 6 month up to 24 months.
Study NCT04072575 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PP6M injection Dose 2
Description: Participants will receive Dose 2 PP6M IM injection at Visit 1 (Day) then once every 6 month up to 24 months.
Study NCT04469426 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interactive online informational and peer support app
Description: The app contains LARS information, bowel function diaries, and online platform with trained peer support mentor
Study NCT00446342 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SNS-032 Injection
Description: Stage 1: Escalating doses of SNS-032 on days 1, 8 and 15 per 28 day cycle~Stage 2: Same as stage 1 except SNS-032 administered at the maximum tolerated dose established in stage 1
Study NCT04537455 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Ultra-high frequency electrocardiography
Description: Patients will have an ultra-high frequency electrocardiography performed.
Study NCT02609503 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: Intensity Modulated Radiation Therapy
Description: Eligible participants will receive Intensity Modulated Radiation Therapy daily x 7 weeks
Study NCT03370835 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metoprolol succinate ER
Description: Cardioselective beta-blocker
Study NCT03370835 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metoprolol succinate ER
Description: Cardioselective beta-blocker
Study NCT01928940 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dabrafenib
Description: 150 mg twice daily
Study NCT01928940 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trametinib
Description: 2 mg once daily
Study NCT02905513 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contraceptive app instant messages
Study NCT02493387 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: The group-based exercise program consists of 60-minute sessions twice a week for 3 months, including central circulatory exercise performed on an ergometer cycle and muscle training, and one or two occasions of home-based exercise. The exercise program are designed after the patients requirements and with the intensity 13-17 on the Borg RPE 6-20 scale
Study NCT02493387 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical activity
Description: The patients randomized PAP will receive a PAP prescription and a physical activity diary. The PAP and physical activity diary will be followed up at 6 and 12 weeks after the inclusion.
Study NCT01012167 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Description: Oxytocin: 24 IU in the morning and 24 IU in the evening given by nasal spray with a total of 6 puffs of the spray, 3 in each nostril at each administration
Study NCT01012167 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Galantamine
Description: Galantamine: 4 mg twice a day for 1 week, then 8 mg twice a day for 1 week, then 12 mg twice a day for 4 weeks
Study NCT01012167 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo-Oxytocin
Description: Saline nasal spray with a total of 6 puffs of the spray, 3 in each nostril at each administration
Study NCT01012167 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo-Oxytocin
Description: Saline nasal spray with a total of 6 puffs of the spray, 3 in each nostril at each administration
Study NCT01012167 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo-Galantamine
Description: Placebo tablets twice a day for 6 weeks
Study NCT01012167 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo-Galantamine
Description: Placebo tablets twice a day for 6 weeks
Study NCT02905513 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Mobile phone app
Study NCT02905513 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobile phone app
Study NCT03063307 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Atraumatic Restorative Treatment
Study NCT02761720 — intervention group
Intervention type: OTHER
Intervention: No Intervention
Study NCT00591071 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strict glycemic control
Description: Continuous intravenous insulin treatment (NOVORAPID) according to an algorithm to maintain glucose level below 6.1 mmol/L
Study NCT03063307 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Silver Diamine Fluoride
Study NCT02408965 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methergine
Description: 0.2 mg of methylergonovine maleate
Study NCT02408965 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: saline placebo to maintain blinding